u/redditroger22

Lc trial (completion date)

• Tvgn489. Ph2 tbd

• 5b8 / thn391. Ph1 Alzheimer

• Maraviroc 2026 04 DL

• Lumbrokinase 2026 12 DL

• Sipavibart. 2026 12

• Truvada 2026 12 DL

• Vyd2311. Tbd ph2 start mid 2026

• Anktiva 2026 10

• Barticinib 2027 12 / 2029? (Ph3)

• Upadacitinib & pirfenidone 2027 12 (Ph 3)

• Abrocitinib 2026 10

• ensitrelvir 2026 12 DL

• Larazotide 2027 04

• daratumumab tbd ph2 2028?

• Rapamycine 2x 2026 06, 2026 12

• Mestinon 2026 11 (& ldn)

• Vericiguat 2026 12 DL

• Inebilizumab / Uplizna ??

• Bezisterim 2026 08 DL

• semaglutide ??

• Tirzepatide 2027 01

• Anakinra 2028 03

• Pembrolizumab (Keytruda) ?? Ph1

So just wanted to share a list of trials that im following and that have potential in symptom relief or cures. DL means delayed. This is mainly phase 2 trials.

Dates are estimated end dates from clinicaltrial.gov

My personal favorite 5b8 is unclear if it will even be trialled for LC. Anyway thought you guys might like this.

Background:

Long COVID affects 10-30% of COVID-19 convalescents, with persistent gut

dysbiosis implicated as a central pathogenic mechanism. Acute infection disrupts gut integrity,

depletes beneficial bacteria (e.g., Faecalibacterium prausnitzii), and expands histamine-

producing pathobionts (e.g., Klebsiella), while diamine oxidase (DAO) activity declines. This

establishes a self-sustaining dysbiotic state that drives systemic endotoxemia, inflammation,

and neuroinflammation, mechanistically linking gut instability to core symptoms such as fatigue,

insomnia, and cognitive dysfunction. Systemic histamine elevation acts as a key

pathophysiological driver, amplifying cytokine storms and neuroinflammation.

Methods:

In a six-month randomized, double-blind trial, 280 Long COVID patients received

either the synbiotic formula SIM01 (Bifidobacterium adolescentis, B. bifidum, B. longum with

galacto-oligosaccharides [GOS], xylooligosaccharides [XOS], resistant dextrin) or placebo (low-

dose vitamin C). Longitudinal multi-omics analysis (stool metagenomics, untargeted

metabolomics, plasma proteomics/cytokine profiling) was performed on 695 stool and 476 blood

samples collected at baseline, six months (end-of-treatment), and 12 months (six-months post-

treatment). Clinical symptom assessments tracked fatigue, insomnia, cognitive symptoms, and

gastrointestinal distress.

Results:

SIM01 induced significant, durable remodeling of the gut microbiome, increasing alpha

diversity and enriching beneficial commensals (F. prausnitzii, Akkermansia muciniphila,

Roseburia hominis) while depleting pathobionts (Ruminococcus gnavus, Clostridium spp.).

Metabolomics revealed a profound reduction in fecal histamine, the most significantly altered

metabolite, persisting at 12 months. Histamine reduction correlated strongly with alleviation of

fatigue, insomnia, memory loss, and dyspnea (FDR<0.05) and decreased plasma IL-1β.

Mechanistically, histamine reduction occurred potentially via: 1) Competitive microbiota

remodeling (SIM01 strains positively correlated with histamine-negative species, negatively with

histamine-positive species); and 2) Enhanced host histamine clearance (significantly increased

plasma DAO activity). Baseline gut microbiota composition accurately predicted SIM01 strain

colonization success and subsequent clinical symptom response (AUC=0.982).

Conclusion:

The synbiotic SIM01 durably reshapes the gut microbiome and reduces histamine

burden in Long COVID patients via a dual mechanism, thereby significantly alleviating core

symptoms such as fatigue and insomnia. Reduced histamine and IL-1β mechanistically link

microbiome remodeling to symptom resolution. Baseline microbiota signatures predict treatment

response, enabling precision deployment of probiotics for Long COVID management and

informing next-generation biotherapeutics.